CTLA4 and infection: Preclinical studies with PD-L1 agonists and CTLA-4 mimetics demonstrated robust plaque reduction in diabetic mouse models; however, establishing a safe and effective dose in humans remains a major barrier, particularly in elderly patients already predisposed to infection and malignancy [142].